# PDUFA dates July 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-07

> 37 FDA catalysts are dated in July 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in July 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104383)) |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104500)) |
| July 2027 | [ALXN1920 primary completion](https://sec-api.dev/pdufa/alxn1920) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07157787 (Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-02 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157787)) |
| July 2027 | [KAI-7535 primary completion](https://sec-api.dev/pdufa/kai-7535) | KLRA | Obesity; Overweight | scheduled | "NCT07497880 (Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-07 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07497880)) |
| July 2027 | [Active imp primary completion](https://sec-api.dev/pdufa/active-imp) | AZN | Liver Fibrosis; Hepatic Cirrhosis | scheduled | "NCT07610837 (Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610837)) |
| July 2027 | [Riliprubart primary completion](https://sec-api.dev/pdufa/riliprubart) | SNY | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06290141 (A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290141)) |
| July 2027 | [Mrna seasonal flu vaccine primary completion](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851246)) |
| July 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | scheduled | "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312176)) |
| July 2027 | [Bomedemstat primary completion](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06079879 (A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079879)) |
| July 2027 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Myelodysplastic Syndromes | scheduled | "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847867)) |
| July 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | scheduled | "NCT05057494 (A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05057494)) |
| July 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07325292)) |
| July 2027 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Anemia | scheduled | "NCT05664737 (A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05664737)) |
| July 2027 | [Luxdegalutamide primary completion](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Prostatic Cancer, Castration-Resistant | scheduled | "NCT07047118 (A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047118)) |
| July 2027 | [Avacopan primary completion](https://sec-api.dev/pdufa/avacopan) | AMGN | Vasculitis | scheduled | "NCT06321601 (Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-18 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06321601)) |
| July 2027 | [EYU688 primary completion](https://sec-api.dev/pdufa/eyu688) | NVS | Dengue | scheduled | "NCT06006559 (A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06006559)) |
| July 2027 | [LXE408 primary completion](https://sec-api.dev/pdufa/lxe408) | NVS | Chagas Disease | scheduled | "NCT06632600 (A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632600)) |
| July 2027 | [MK-8527 primary completion](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07044297 (A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044297)) |
| July 2027 | [PF-07248144 primary completion](https://sec-api.dev/pdufa/pf-07248144) | PFE | Breast Cancer | scheduled | "NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07062965)) |
| July 2027 | [VX-407 primary completion](https://sec-api.dev/pdufa/vx-407) | VRTX | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | scheduled | "NCT07161037 (Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07161037)) |
| July 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Sickle Cell Disease | scheduled | "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975865)) |
| July 2027 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Primary Hyperaldosteronism | scheduled | "NCT07007793 (Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007793)) |
| July 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06103864)) |
| July 2027 | [GXV813 primary completion](https://sec-api.dev/pdufa/gxv813) | NVS | Schizophrenia | scheduled | "NCT07467993 (Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07467993)) |
| July 2027 | [TABRECTA (capmatinib) primary completion](https://sec-api.dev/pdufa/capmatinib) | NVS | Advanced Solid Tumors Which Are cMET-dependent | scheduled | "NCT03040973 (Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03040973)) |
| July 2027 | [ATEBRIOZ® (zilurgisertib) primary completion](https://sec-api.dev/pdufa/zilurgisertib) | INCY | Fibrodysplasia Ossificans Progressiva (FOP) | scheduled | "NCT05090891 (To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05090891)) |
| July 2027 | [Qbrexza (glycopyrronium tosylate) primary completion](https://sec-api.dev/pdufa/glycopyrronium) | NVS | Asthma | scheduled | "NCT05222529 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222529)) |
| July 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05455320)) |
| July 2027 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | scheduled | "NCT06072183 (A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06072183)) |
| July 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06448754 (Volrustomig Priming Regimens Exploratory Phase II Platform Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06448754)) |
| July 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Diffuse Cutaneous Systemic Sclerosis | scheduled | "NCT06470048 (A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470048)) |
| July 2027 | [Acasunlimab primary completion](https://sec-api.dev/pdufa/acasunlimab) | GMAB | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | scheduled | "NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635824)) |
| July 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolaemia | scheduled | "NCT07619131 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619131)) |
| July 2027 | [Vonaprument primary completion](https://sec-api.dev/pdufa/vonaprument) | ANNX | Geographic Atrophy | scheduled | "NCT06510816 (A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06510816)) |
| July 2027 | [6-thio-2'-deoxyguanosine primary completion](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small -Cell Lung | scheduled | "NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06908304)) |
| July 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Multiple Sclerosis | scheduled | "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503873)) |
| July 2027 | [Abp 938 8 mg primary completion](https://sec-api.dev/pdufa/abp-938) | AMGN | Neovascular Age-related Macular Degeneration; nAMD | scheduled | "NCT07614776 (A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614776)) |

Other months: https://sec-api.dev/fda-calendar/2027-06 , https://sec-api.dev/fda-calendar/2027-08. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates July 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-07

```bibtex
@misc{secapidev_fda_calendar_2027_07_20261116,
  title        = {PDUFA dates July 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-07}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_07_20261116","title":"PDUFA dates July 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-07","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
